logo

For the Inventor, By the Inventor

Ibaraki, Japan

Koukichi Harada

This inventor holds 26 USPTO granted patents, plus 1 CIPO patent, primarily in Pharmaceutical Compounds. Top assignee: Eisai Company, Limited. Active years: 1988-1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Koukichi Harada. Retrieved from https://idiyas.com/inventor/koukichi-harada

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 26

% Patents Active = 100.0


Average Co-Inventor Count = 13.6

ph-index = 4

Forward Citations = 55(Granted Patents)


Location History:

  • Yatabe, JP (1988)
  • Tsukuba, JP (1989)
  • Yatabemachi, JP (1990 - 1993)
  • Ibaraki, JP (1991 - 1998)

Company Filing History:

goldMedal26 out of 677 
 
Eisai Company, Limited
 patents

Years Active: 1988-1998

Loading Chart...
Loading Chart...
Areas of Expertise:
Glycerin Derivative
1,4-Diazepine Derivative
Triazolo-1,4-Diazepine
Pharmaceutical Use
Naphthalene Derivatives
Diphenylethylene Derivatives
Benzophenone Compounds
Polyprenyl Compound
26 patents (USPTO):Explore Patents
1. 5854279 - Therapeutic agent for dermatosis (1998-12-29),
2. 5482937 - 1,4-diazepine derivative and its pharmaceutical use (1996-01-09),
3. 5476864 - Glycerin derivative and its pharmacological use (1995-12-19),
4. 5476863 - Glycerin derivative and its pharmacological use (1995-12-19),
5. 5468740 - 1,4-diazepine derivative and its pharmaceutical use (1995-11-21),
6. 5438045 - 1,4-diazepine derivative and its pharmaceutical use (1995-08-01),
7. 5409909 - 1,4-diazepine derivative and its pharmaceutical use (1995-04-25),
8. 5382579 - Triazolo-1,4-diazepine derivatives and their use in pharmaceuticals (1995-01-17),
9. 5329010 - Quinone derivatives (1994-07-12),
10. 5319139 - Naphthalene derivatives (1994-06-07),
11. 5304553 - 1,4-diazepine derivative and its pharmaceutical use (1994-04-19),
12. 5273985 - Glycerin derivative and its pharmacological use (1993-12-28),
13. 5262565 - Naphthalene derivatives (1993-11-16),
14. 5237091 - Naphthalene derivatives (1993-08-17),
15. 5221671 - Triazolo-1,4-diazepine derivatives and their use in pharmaceuticals (1993-06-22),

Title: The Inventor Spotlight: Koukichi Harada

Introduction:

Koukichi Harada, a prolific inventor hailing from Ibaraki, Japan, has made significant contributions in the field of pharmaceuticals with a remarkable portfolio of 26 patents to his name.

Latest Patents:

Harada's recent patents include a groundbreaking therapeutic agent for dermatosis, designed to prevent, treat, or ameliorate non-infectious dermatosis such as psoriasis and atopic dermatitis. Additionally, his innovative 1,4-diazepine derivative has shown promise in treating allergic diseases, marking another milestone in his inventive career.

Career Highlights:

Koukichi Harada is affiliated with Eisai Company, Limited, a prominent pharmaceutical company known for its cutting-edge research and development initiatives. His association with Eisai Company has provided a conducive environment for him to nurture his innovative ideas and translate them into groundbreaking inventions.

Collaborations:

In his esteemed career, Harada has collaborated closely with notable individuals in the field, including Isao Yamatsu and Shinya Abe. Together, they have synergized their expertise to push the boundaries of pharmaceutical innovation and address critical medical needs with their pioneering solutions.

Conclusion:

Koukichi Harada's relentless pursuit of excellence and his unwavering commitment to innovation have established him as a trailblazer in the pharmaceutical industry. His patented inventions not only showcase his technical acumen but also reflect his dedication to improving healthcare outcomes and enhancing quality of life for patients worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…